TY - JOUR
T1 - Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
AU - on behalf of the ERACE-PA Global Study Group
AU - Gill, Christian M.
AU - Nicolau, David P.
AU - Aktas, Elif
AU - Alfouzan, Wadha
AU - Bourassa, Lori
AU - Brink, Adrian
AU - Burnham, Carey Ann D.
AU - Canton, Rafael
AU - Carmeli, Yehuda
AU - Falcone, Marco
AU - Kiffer, Carlos
AU - Marchese, Anna
AU - Martinez, Octavio
AU - Pournaras, Spyros
AU - Satlin, Michael
AU - Seifert, Harald
AU - Thabit, Abrar K.
AU - Thomson, Kenneth S.
AU - Villegas, Maria Virginia
AU - Wille, Julia
AU - Rezende, Thais Teles Freitas
AU - Cekin, Zuhal
AU - Malkocoglu, Gulsah
AU - Gijón, Desirèe
AU - Tarakmeh, Layla Abdullah
AU - Chu, Chun Yat
AU - Opperman, Christoffel Johannes
AU - Tootla, Hafsah Deepa
AU - Moodley, Clinton
AU - Coetzee, Jennifer
AU - Vourli, Sophia
AU - Dimopoulos, George
AU - Attallah, Dalya M.
AU - Tiseo, Giusy
AU - Leonildi, Alessandro
AU - Giordano, Cesira
AU - Barnini, Simona
AU - Menichetti, Francesco
AU - Pilato, Vincenzo Di
AU - Codda, Giulia
AU - Vena, Antonio
AU - Giacobbe, Daniele Roberto
AU - Westblade, Lars
AU - Cardona, Armando
AU - Curtis, Lauren
AU - Fang, Ferric
AU - Thomson, Gina
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Objectives: To evaluate the genotypic and ceftazidime/avibactam-susceptibility profiles amongst ceftolozane/tazobactam-non-susceptible (NS), MBL-negative Pseudomonas aeruginosa in a global surveillance programme. Methods: Isolates were collected as part of the ERACE-PA Global Surveillance programme. Carbapenem-resistant P. aeruginosa deemed clinically relevant by the submitting laboratories were included. Broth microdilution MICs were conducted per CLSI standards to ceftolozane/tazobactam, ceftazidime/avibactam, ceftazidime and cefepime. Genotypic carbapenemases were detected using CarbaR and CarbaR NxG (research use only). Isolates negative for carbapenemases by PCR were assessed via WGS. Isolates were included in the analysis if they were ceftolozane/tazobactam-NS and lacked detection of known MBLs. Results: Of the 807 isolates collected in the ERACE-PA programme, 126 (16%) were ceftolozane/tazobactam-NS and lacked MBLs. Cross-resistance to ceftazidime and cefepime was common, with only 5% and 16% testing susceptible, respectively. Ceftazidime/avibactam retained in vitro activity, with 65% of isolates testing susceptible. GES was the most common enzymology, detected in 57 (45%) isolates, and 89% remained susceptible to ceftazidime/avibactam. Seven isolates harboured KPC and all tested susceptible to ceftazidime/avibactam. In the remaining 62 isolates, WGS revealed various ESBLs or OXA β-lactamases. While 39% remained susceptible to ceftazidime/avibactam, marked variability was observed among the diverse resistance mechanisms. Conclusions: Ceftazidime/avibactam remained active in vitro against the majority of ceftolozane/tazobactam-NS, MBL-negative P. aeruginosa. Ceftazidime/avibactam was highly active against isolates harbouring GES and KPC β-lactamases. These data highlight the potential clinical utility of genotypic profiling as well as the need to test multiple novel agents when carbapenem-resistant P. aeruginosa are encountered.
AB - Objectives: To evaluate the genotypic and ceftazidime/avibactam-susceptibility profiles amongst ceftolozane/tazobactam-non-susceptible (NS), MBL-negative Pseudomonas aeruginosa in a global surveillance programme. Methods: Isolates were collected as part of the ERACE-PA Global Surveillance programme. Carbapenem-resistant P. aeruginosa deemed clinically relevant by the submitting laboratories were included. Broth microdilution MICs were conducted per CLSI standards to ceftolozane/tazobactam, ceftazidime/avibactam, ceftazidime and cefepime. Genotypic carbapenemases were detected using CarbaR and CarbaR NxG (research use only). Isolates negative for carbapenemases by PCR were assessed via WGS. Isolates were included in the analysis if they were ceftolozane/tazobactam-NS and lacked detection of known MBLs. Results: Of the 807 isolates collected in the ERACE-PA programme, 126 (16%) were ceftolozane/tazobactam-NS and lacked MBLs. Cross-resistance to ceftazidime and cefepime was common, with only 5% and 16% testing susceptible, respectively. Ceftazidime/avibactam retained in vitro activity, with 65% of isolates testing susceptible. GES was the most common enzymology, detected in 57 (45%) isolates, and 89% remained susceptible to ceftazidime/avibactam. Seven isolates harboured KPC and all tested susceptible to ceftazidime/avibactam. In the remaining 62 isolates, WGS revealed various ESBLs or OXA β-lactamases. While 39% remained susceptible to ceftazidime/avibactam, marked variability was observed among the diverse resistance mechanisms. Conclusions: Ceftazidime/avibactam remained active in vitro against the majority of ceftolozane/tazobactam-NS, MBL-negative P. aeruginosa. Ceftazidime/avibactam was highly active against isolates harbouring GES and KPC β-lactamases. These data highlight the potential clinical utility of genotypic profiling as well as the need to test multiple novel agents when carbapenem-resistant P. aeruginosa are encountered.
UR - http://www.scopus.com/inward/record.url?scp=85144596308&partnerID=8YFLogxK
U2 - 10.1093/jac/dkac385
DO - 10.1093/jac/dkac385
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36411249
AN - SCOPUS:85144596308
SN - 0305-7453
VL - 78
SP - 252
EP - 256
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 1
ER -